Use of catecholamines and related compounds as anti-angiogenic agents

Abstract

The present invention provides a pharmaceutical composition comprising at least one compound selected from the group consisting of (S)-isoproterenol, (S)-isoproterenol dipivalate, (S)—N-ethylnoradrenaline, (S)—N-n-Propylnoradrenaline, (S)—N-Butylnoradrenaline, (R, S)—N-tert-butylnoradrenaline, 1-(3, 4) dihydrooxylphenyl)-2-(isopropylamine)-1-(R, S)-butanol, (S)-1-(N-isopropyl)-3-methyldopamine and (R)-1-(N-isopropyl)-3-methyldopamine suitable. The pharmaceutical composition may be for topical application to ocular tissues.

1 . A pharmaceutical composition comprising at least one compound selected from the group consisting of (S)-isoproterenol, (S)-isoproterenol dipivalate, (S)—N-ethylnoradrenaline, (S)—N-n-Propylnoradrenaline, (S)—N-Butylnoradrenaline, (R, S)—N-tert-butylnoradrenaline, 1-(3, 4) dihydrooxylphenyl)-2-(isopropylamine)-1-(R, S)-butanol, (S)-1-(N-isopropyl)-3-methyldopamine or (R)-1-(N-isopropyl)-3-methyldopamine, for topical application to ocular tissues. 
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein the compound has an optical purity of 95% or greater. 
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the compound has an optical purity of 97% or greater. 
     
     
         4 . A pharmaceutical composition according to  claim 1 , wherein the compound has an optical purity of 99% or greater. 
     
     
         5 . A pharmaceutical composition according to  claim 1 , wherein the compound is (S)-isoproterenol or (S)-isoproterenol dipivalate. 
     
     
         6 . A pharmaceutical composition according to  claim 1 , wherein the compound is formulated with a prodrug. 
     
     
         7 . A pharmaceutical composition according to  claim 1 , further comprising one or more pharmacologically tolerated ingredients for topical application to ocular tissues. 
     
     
         8 . A pharmaceutical composition according to  claim 1 , wherein the compound is (S)-isoproterenol dipivalate, and wherein said compound is formulated suitable for topical delivery to ocular tissues. 
     
     
         9 . A pharmaceutical composition according to  claim 1 , wherein the compound is (S)-isoproterenol dipivalate, and wherein said compound is formulated for various administrations suitable to ocular tissues.